Tyra Biosciences’ (TYRA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

A number of other brokerages also recently weighed in on TYRA. Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Price Performance

Shares of TYRA opened at $15.10 on Monday. Tyra Biosciences has a 1 year low of $12.17 and a 1 year high of $29.60. The company has a market capitalization of $764.11 million, a price-to-earnings ratio of -9.38 and a beta of 1.04. The business has a 50-day moving average of $15.45 and a 200-day moving average of $19.22.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, sell-side analysts anticipate that Tyra Biosciences will post -1.57 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In related news, CFO Alan Fuhrman bought 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares in the company, valued at approximately $205,584. This represents a 283.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the transaction, the chief executive officer now directly owns 1,355,927 shares in the company, valued at approximately $37,830,363.30. The trade was a 1.39 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 74,125 shares of company stock valued at $1,583,097. Company insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. American Century Companies Inc. boosted its position in shares of Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after buying an additional 145,346 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after acquiring an additional 338,208 shares during the period. Janus Henderson Group PLC bought a new stake in Tyra Biosciences during the third quarter worth $24,994,000. Ensign Peak Advisors Inc bought a new stake in Tyra Biosciences during the second quarter worth $3,047,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Tyra Biosciences during the third quarter worth $593,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.